Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

[1]  A. Vivancos,et al.  102P HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer: A correlative analysis of 757 patients from the Sweden Cancerome Analysis Network - Breast (SCAN-B) dataset , 2023, ESMO Open.

[2]  C. Perou,et al.  Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. , 2023, JAMA oncology.

[3]  C. Perou,et al.  Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. , 2023, JAMA oncology.

[4]  A. Schneeweiss,et al.  Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy , 2023, npj Breast Cancer.

[5]  M. Piccart,et al.  VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up , 2022, Annals of Oncology.

[6]  E. Winer,et al.  A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer , 2022, NPJ breast cancer.

[7]  C. Perou,et al.  Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer , 2022, EBioMedicine.

[8]  D. Berry,et al.  Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial , 2021, Nature Communications.

[9]  C. Perou,et al.  Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy , 2021, Clinical Cancer Research.

[10]  R. Gelber,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Somerfield,et al.  Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Berry,et al.  Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Hauptmann,et al.  LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results , 2020 .

[14]  Charles M. Perou,et al.  HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. , 2020, Cancer treatment reviews.

[15]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Tournigand,et al.  6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial , 2019, The Lancet.

[17]  P. Fasching,et al.  Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Caldas,et al.  6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial , 2019, The Lancet.

[19]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[20]  N. Biglia,et al.  Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Neven,et al.  Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The SOLD Randomized Clinical Trial , 2018, JAMA oncology.

[22]  S. Park,et al.  Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction. , 2018, Radiology.

[23]  P. Nuciforo,et al.  HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. , 2017, The Lancet. Oncology.

[24]  M. Dowsett,et al.  Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer , 2017, Breast Cancer Research.

[25]  E. Perez,et al.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Berry,et al.  Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Pusztai,et al.  Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  V. Georgoulias,et al.  Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[30]  S. Paik,et al.  Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.

[31]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[32]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[33]  R. Gelber,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.

[34]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.